TCGA-GV-A3JW-01A-11R-A20F-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 21.32063075
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.190
- SPERMATOGENESIS+0.140
- PEROXISOME+0.100
- PROTEIN_SECRETION+0.100
- BILE_ACID_METABOLISM+0.090
- CHOLESTEROL_HOMEOSTASIS+0.080
- UNFOLDED_PROTEIN_RESPONSE+0.070
- E2F_TARGETS+0.050
- KRAS_SIGNALING_DN+0.050
- MITOTIC_SPINDLE+0.020
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.630
- IL6_JAK_STAT3_SIGNALING-0.610
- ALLOGRAFT_REJECTION-0.600
- INTERFERON_GAMMA_RESPONSE-0.560
- TNFA_SIGNALING_VIA_NFKB-0.560
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.510
- INFLAMMATORY_RESPONSE-0.490
- APOPTOSIS-0.450
- COMPLEMENT-0.430
- ANGIOGENESIS-0.420
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-DK-AA76-01A-11R-A39I-07 | — | — | 0.932 |
| 2 | TCGA-ZF-A9RL-01A-11R-A38B-07 | — | — | 0.921 |
| 3 | TCGA-G2-A3VY-01A-11R-A22U-07 | — | — | 0.919 |
| 4 | TCGA-GU-A42P-01A-11R-A23W-07 | — | — | 0.915 |
| 5 | TCGA-LQ-A4E4-01A-11R-A266-07 | — | B | 0.904 |
| 6 | SRR1322163 | GTEX | — | 0.901 |
| 7 | SRR1442356 | GTEX | — | 0.898 |
| 8 | TCGA-CN-6988-01A-11R-1915-07 | — | — | 0.897 |
| 9 | TCGA-FJ-A3ZE-01A-11R-A23N-07 | — | — | 0.896 |
| 10 | TCGA-G2-AA3F-01A-12R-A42T-07 | — | — | 0.895 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.190 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.080 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.070 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.050 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.050 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.020 | Inavolisib | — uncovered |